Shire Could Get More Out Of OPUS-3 Than Refiling Lifitegrast
This article was originally published in Scrip
In addition to supporting resubmission of the new drug application (NDA) for Shire PLC's dry-eye disease candidate lifitegrast, the specialty pharma is emphasizing that the just-completed OPUS-3 trial shows that lifitegrast is the first drug ever to demonstrate symptom improvement over consecutive trials in dry eye.
You may also be interested in...
By examining the "totality of the data" including a Phase II study, FDA approved drug for both measures of dry eye, despite mixed results in pivotal trials.
Shire's Danish chief executive says completing the Baxalta merger will greatly boost the group's exposure to longer acting orphan drugs, bring critical mass and de-risk its current asset mix with new portfolio products; a view widely shared by investors and analysts.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.